Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119255 | 0.90 | CASP3 (0.51) | CASP3PTPN1KMT2AMDM4TP53 | |
| SCHEMBL29401661 | 0.90 | CASP3 (0.51) | CASP3PTPN1KMT2AMDM4TP53 | |
| SCHEMBL31520524 | 0.89 | MDM2 (0.49) | L3MBTL1CASP3KMT2AMDM4TP53 | |
| SCHEMBL2481585 | 0.86 | CASP3 (0.50) | L3MBTL1CASP3KMT2AMDM4TP53 | |
| SCHEMBL21645558 | 0.86 | CASP3 (0.50) | L3MBTL1CASP3KMT2AMDM4TP53 | |
| SCHEMBL2481578 | 0.86 | CASP3 (0.50) | L3MBTL1CASP3KMT2AMDM4TP53 | |
| SCHEMBL16075059 | 0.86 | PTPN1 (0.49) | PTPN1MDM4TP53MDM2 | |
| SCHEMBL117946 | 0.86 | MDM4 (0.51) | CASP3PTPN1MDM4TP53MDM2 | |
| SCHEMBL119588 | 0.86 | MDM4 (0.51) | CASP3PTPN1MDM4TP53MDM2 | |
| SCHEMBL31714182 | 0.86 | MDM4 (0.51) | CASP3PTPN1MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025264785-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023185156-A9 | POLYPEPTIDE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国医学科学院医药生物技术研究所 | 2024-01-11 | — | — | WO | disclosed |
| WO-2023185156-A1 | POLYPEPTIDE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国医学科学院医药生物技术研究所 | 2023-10-05 | — | — | WO | disclosed |
| CN-116199737-A | Low-molecular human epidermal cell autophagy regulating peptide DKX-9 and application thereof | 广州好美生物工程技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| CN-115943151-A | Process for the preparation of GLP-1/glucagon dual agonists | 伊莱利利公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-4110800-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | L3MBTL1 1711/4885CASP3 3659/4885PTPN1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.